Literature DB >> 26869172

MicroRNAs in heart failure: from biomarker to target for therapy.

Eline L Vegter1, Peter van der Meer1, Leon J de Windt2, Yigal M Pinto3, Adriaan A Voors1.   

Abstract

MicroRNAs (miRNAs) are increasingly recognized to play important roles in cardiovascular diseases, including heart failure. These small, non-coding RNAs have been identified in tissue and are involved in several pathophysiological processes related to heart failure, such as cardiac fibrosis and hypertrophy. As a result, miRNAs have become interesting novel drug targets, leading to the development of miRNA mimics and antimirs. MicroRNAs are also detected in the circulation, and are proposed as potential diagnostic and prognostic biomarkers in heart failure. However, their role and function in the circulation remains to be resolved. Here, we review the potential roles of miRNAs as circulating biomarkers and as targets for therapy.
© 2016 The Authors. European Journal of Heart Failure © 2016 European Society of Cardiology.

Entities:  

Keywords:  Antimir; Circulation; Heart failure; MicroRNAs

Mesh:

Substances:

Year:  2016        PMID: 26869172     DOI: 10.1002/ejhf.495

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  96 in total

1.  The crosstalk of HDAC3, microRNA-18a and ADRB3 in the progression of heart failure.

Authors:  Jingtao Na; Haifeng Jin; Xin Wang; Kan Huang; Shuang Sun; Qiang Li; Wenting Zhang
Journal:  Cell Biosci       Date:  2021-02-06       Impact factor: 7.133

2.  Decreased Expression of Plasma MicroRNA in Patients with Methamphetamine (MA) Use Disorder.

Authors:  Yan Zhao; Kai Zhang; Haifeng Jiang; Jiang Du; Zong Na; Wei Hao; Shunying Yu; Min Zhao
Journal:  J Neuroimmune Pharmacol       Date:  2016-04-23       Impact factor: 4.147

Review 3.  Role of circulating factors in cardiac aging.

Authors:  Antonio Cannatà; Gabriella Marcon; Giovanni Cimmino; Luca Camparini; Giulio Ciucci; Gianfranco Sinagra; Francesco S Loffredo
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

4.  Pharmacological Silencing of MicroRNA-152 Prevents Pressure Overload-Induced Heart Failure.

Authors:  Thomas J LaRocca; Timon Seeger; Maricela Prado; Isaac Perea-Gil; Evgenios Neofytou; Brigham H Mecham; Mohamed Ameen; Alex Chia Yu Chang; Gaurav Pandey; Joseph C Wu; Ioannis Karakikes
Journal:  Circ Heart Fail       Date:  2020-03-12       Impact factor: 8.790

Review 5.  Noncoding RNAs: potential regulators in cardioncology.

Authors:  Shambhabi Chatterjee; Shashi Kumar Gupta; Christian Bär; Thomas Thum
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-11-09       Impact factor: 4.733

Review 6.  Cardiomyokines from the heart.

Authors:  Ayano Chiba; Haruko Watanabe-Takano; Takahiro Miyazaki; Naoki Mochizuki
Journal:  Cell Mol Life Sci       Date:  2017-12-13       Impact factor: 9.261

Review 7.  Biomarkers in cardiovascular disease: Statistical assessment and section on key novel heart failure biomarkers.

Authors:  Ravi Dhingra; Ramachandran S Vasan
Journal:  Trends Cardiovasc Med       Date:  2016-07-28       Impact factor: 6.677

8.  Clinical significance of sFRP5, RBP-4 and NT-proBNP in patients with chronic heart failure.

Authors:  Yu An; Qingsong Wang; Hong Wang; Na Zhang; Fengming Zhang
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

9.  Marked disparity of microRNA modulation by cGMP-selective PDE5 versus PDE9 inhibitors in heart disease.

Authors:  Kristen M Kokkonen-Simon; Amir Saberi; Taishi Nakamura; Mark J Ranek; Guangshuo Zhu; Djahida Bedja; Michaela Kuhn; Marc K Halushka; Dong Ik Lee; David A Kass
Journal:  JCI Insight       Date:  2018-08-09

Review 10.  Dysregulated micro-RNAs and long noncoding RNAs in cardiac development and pediatric heart failure.

Authors:  Lee S Toni; Frehiwet Hailu; Carmen C Sucharov
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-03-27       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.